drugset / Trial / NCT05765279

A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2

NCT05765279

Completed 281 enrolled Beijing Ditan Hospital
RandomizedParallel-groupSingle-blindPrevention

Summary

An Investigator-initiated, Randomized, Single-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of SARS-Cov-2 Post Exposure Prophylaxis and Safety of HH-120 nasal spray

Timeline

Start
2022-10-20
Primary completion
2022-12-06
Completion
2022-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HH-120 Protein / enzyme biologic Intranasal

Indications